Tonix Pharmaceuticals : Investor Factsheet

NASDAQ: TNXP

HQ: Chatham, NJ

$140M of Cash

As of 9/30/22

investor.relations@

tonixpharma.com

MANAGEMENT TEAM

Seth Lederman, MD

Co-Founder, CEO & Chairman

Gregory Sullivan, MD

Chief Medical Officer

Bradley Saenger, CPA

Chief Financial Officer

What We Do

Tonix is committed to improving population health by inventing and developing innovative therapies and vaccines, through broad in- house capabilities and creative collaborations, to help address important unmet needs.

Leveraging the expertise of the Company's leaders, Tonix's strategy includes:

• Development of a diverse yet curated portfolio, including small molecule drugs and biologics, across a range of therapeutic areas
• Investment in domestic, in-house, R&D and manufacturing to accelerate development timelines and improve the ability to respond to pandemics
• Partnering strategically with other biotech companies, world-class academic and non-profit research organizations to bring innovative therapeutics to market faster

Therapeutic Areas

Jessica Morris

Chief Operating Officer

MAIN U.S. OFFICES

New Jersey Office

(Corporate Headquarters)

26 Main Street - Ste 101

Chatham, NJ 07928

New York Office

509 Madison Ave. - Ste 1608 New York, NY 10022

Research and Development Center (RDC)

431 Aviation Way Frederick, MD 21701

Advanced Development Center (ADC)

259 Samuel Barnet Blvd

New Bedford Business Park

North Dartmouth, MA 02745

www.tonixpharma.com

@TonixPharma

Central Nervous

System

Immunology

Infectious

Disease

Rare

Disease

Tonix is dedicated to finding treatments for difficult-to-treat, widely occurring, chronic disorders of the central nervous system including pain, neurologic, psychiatric and addiction conditions, using non-opioid,non-addictive therapies.

Tonix is advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.

Tonix is targeting pathogenic infections, including monkeypox and smallpox for biodefense, as well as the ongoing COVID-19 pandemic. Through its live virus vaccine platform and in-house capabilities, Tonix strives to be prepared for future pandemics.

Tonix is developing novel therapies for patients with rare diseases, including those caused by genetic disorders which are characterized by complex symptoms and for which no drug is approved.

Development Pipeline: Key Product Candidates

Using our integrated development engine, we advance innovative programs into the clinic

Central Nervous System

TNX-102SL Fibromyalgia (FM) Confirmatory Phase 3: initiated 2Q 2022 Interim analysis results: expected 2Q 2023

TNX-102SL Posttraumatic Stress Disorder (PTSD)

Phase 2 start: targeting 2Q 2023

TNX-102 SL Long COVID Phase 2: initiated 3Q 2022

Interim analysis results: expected 3Q 2023

TNX-601ER Major Depressive Disorder

Phase 2: targeting 1Q 2023

TNX-1300 Cocaine Intoxication/Overdose

Phase 2 start: targeting 1Q 2023

TNX-1900 Chronic Migraine

Phase 2 start: targeting 1Q 2023

Status	Small Molecule	Biologic /	Monoclonal
Small Peptide	Antibody (mAb)

Mid-Phase 3	+
Phase 2 ready	+
Phase 2	+
Phase 2 ready	+
Mid-Phase 2	+
Phase 2 ready	+

Immunology

	Status	Small Molecule	Biologic /	Monoclonal
	Small Peptide	Antibody (mAb)
TNX-1500 Organ Transplant				+
Rejection/Autoimmune Disorders	Preclinical
Phase 1 start: targeting 1H 2023
TNX-1700 Gastric and Colorectal Cancers	Preclinical		+

Infectious Disease

TNX-801 Smallpox and Monkeypox Vaccine Phase 1 start: targeting 2H 2023

TNX-1850 COVID-19 Vaccine

Status	Small Molecule	Biologic /	Monoclonal
Small Peptide	Antibody (mAb)
Preclinical		+
Preclinical		+

Rare Disease

	Status	Small Molecule	Biologic /	Monoclonal
	Small Peptide	Antibody (mAb)
TNX-2900 Prader-Willi Syndrome	Preclinical		+
Orphan Drug Designation

*All of Tonix's product candidates are investigational new drugs or biologics and have not been approved for any indication. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. We cannot predict whether the global COVID-19 pandemic will impact the timing of these milestones.

Our Facilities

We are building out our internal R&D and manufacturing capabilities in the US

	Research and Development Center		Advanced Development Center		Commercial Manufacturing Center
	(RDC)		(ADC)		(CMC)
Function	Accelerated development of vaccines and		Development and clinical scale		Phase 3 and Commercial scale
antiviral drugs for COVID-19, its variants
	manufacturing of biologics		manufacturing of biologics
	and other infectious diseases
Description	~48,000 square feet, BSL-2 with some		~45,000 square feet, BSL-2		~44 acre green field site, planned BSL-2
areas designated BSL-3
Status	Operational		Operational		Planning for site enabling work in 2023
Location	Frederick, Maryland		North Dartmouth, Massachusetts		Hamilton, Montana

© 2022 Tonix Pharmaceuticals Holding Corp.

All rights reserved.